Introduction
The ACR recommendations for the treatment of Juvenile Idiopathic Arthritis (ACR-JIA) were published in 2011 with the aim of providing an evidence-based therapeutic pathway for effective JIA treatment.
Objectives
Our aim was to determine the feasibility of applying ACR-JIA to a real-life paediatric JIA cohort and to evaluate the treatment pathway of those children.
Methods
We conducted a retrospective analysis of a single-centre paediatric JIA cohort. This included a review of the patient case notes, radiology and drug monitoring data of all children with JIA diagnosed with multi-joint (5 or more joint) disease in the 2 years since ACR-JIA were published.In total, 35 patients fulfilled ILAR criteria for the diagnosis of JIA since 2011: systemic arthritis (n=5), polyarthritis (n=25) and extended Oligoarthritis (n=5). Duration to Methotrexate and Etanercept treatments was calculated, and the frequency of drug monitoring noted.
Results 25 females and 10 males (median age at onset 13, range 1.5-15 years) were included in the evaluation. Median age at disease onset for poly/extended oligoarthritis was 10 years (1.5-16), with a median of 12 joints (12-38) active at presentation, and for the systemic group median age at onset was 6 years (2-7), with a median number of 6 active joints (2-10). 3 polyarthritis patients were rheumatoid factor positive (0 extended oligoarthritis and 0 systemics). 22/30 patients with polyarthritis/extended oligoarthritis followed the ACR recommendations for treatment according to their disease severity, commen-1 Paediatric Rheumatology, Birmingham Children's Hospital, UK Full list of author information is available at the end of the article 
Conclusion
Overall, 27/35 patients followed the ACR-JIA recommendations. This evaluation highlights the difficulty of achieving rapid commencement of new JIA therapies and the challenging of regular drug monitoring.
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